Wenxin Feng
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Spatially resolved structure-function mapping of the anterior cruciate ligament-bone interface : regional variation in microarchitecture, tensile properties, and stress distribution.
Journal: Bone & joint research
Published: November 11, 2025
NSD2 inhibits the expression of PD-L1 via oxidative phosphorylation to control immune surveillance in hepatocellular carcinoma.
Journal: Cell death & disease
Published: July 19, 2025
Histone 3 lysine 36 trimethylation by SETD2 shapes an epigenetic landscape in intestinal stem cells to orchestrate lipid metabolism and attenuate cell senescence.
Journal: Cell death & disease
Published: June 14, 2025
Ribosome Homeostasis Regulated by SETD2 Preserves Intestinal Epithelial Barrier.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 06, 2025
NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling.
Journal: Oncogene
Published: February 07, 2025
Targeted delivery of Grem1 and IL-10 separately by mesenchymal stem cells effectively mitigates SETD2-deficient inflammatory bowel disease.
Journal: Theranostics
Published: October 26, 2024
PTPRT loss enhances anti-PD-1 therapy efficacy by regulation of STING pathway in non-small cell lung cancer.
Journal: Science translational medicine
Published: September 04, 2024
Epithelial NSD2 maintains FMO-mediated taurine biosynthesis to prevent intestinal barrier disruption.
Journal: Clinical and translational medicine
Published: August 09, 2024
Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 03, 2023
Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
Journal: Cancer letters
Published: August 10, 2023
Loss of SETD2 aggravates colorectal cancer progression caused by SMAD4 deletion through the RAS/ERK signalling pathway.
Journal: Clinical and translational medicine
Published: June 15, 2023
SETD2 deficiency promotes renal fibrosis through the TGF-β/Smad signalling pathway in the absence of VHL.
Journal: Clinical and translational medicine
Published: April 10, 2023
Last Updated: 09/26/2026